addarrow-downarrow-leftarrow-rightarrow-up82CF3E98-D323-4B3E-9EDD-EF2E73FB5C9E@1xcancelclosedowndownloademailIcons / Social / FacebookfilterhomeIcons / Social / InstagramleftIcons / Social / LinkedIn895A4639-EEE0-4BEB-B7D1-CAB21217861B@1xMenu IconremoverightSearchtagtik-toktimeline-arrow-lefttranslateIcons / Social / TwitterupIcons / Social / YouTube

Dr Deanna Hagge

Dr Deanna Hagge

Deanna brings 25 years of experience in collaborative and global leprosy research: 10 years of laboratory-based research with the US National Hansen’s Disease Programs and 15 years in endemic field laboratory, clinical and community-based research studies.

She is the Scientific Research Representative on the Global Partnership for Zero Leprosy (GPZL) Leadership Team.

Mobile: +1-225-202-7118

Leprosy Global Consortium or Multi-centric Study Experience

  • Erythema Nodosum Leprosum (ENL) International Study Group (ENLIST) - including the current Methotrexate and Prednisolone Study (MaPS) in ENL Clinical Trial
  • World Health Organization (WHO) Global Surveillance Program for Leprosy Drug Resistance
  • Treatment of Early Neuritis in Leprosy (TENLEP) Clinical Trials
  • Initiative for Diagnostics and Epidemiological Assays for Leprosy (IDEAL)
  • Development of the Molecular Viability Assay (MVA) to determine Mycobacterium leprae viability in the clinical setting
  • Host Genetics and Susceptibility to Leprosy
  • Clinical trial-related publications
  • Transforming the Treatment and Prevention of Leprosy and Buruli Ulcers in Low- and Middle-Income Countries (LMICs) funded by UK National Institutes of Health Research (NIHR) Research and Innovation for Global Health (RIGHT): – includes a wound healing clinical trial.


  1. A Sensitive and Quantitative Assay to Enumerate and Measure Mycobacterium leprae Viability in Clinical and Experimental Specimens. Collins JH, Lenz SM, Ray NA, Balagon MF, Hagge DA, Lahiri R, Adams LB. Curr Protoc. 2022 Feb;2(2):e359. doi: 10.1002/cpz1.359. PMID: 35113486
  2. A simple assay to quantify mycobacterial lipid antigen-specific T cell receptors in human tissues and blood. Zhou AX, Scriba TJ, Day CL, Hagge DA, Seshadri C. PLoS Negl Trop Dis. 2021 Dec 16;15(12):e0010018. doi: 10.1371/journal.pntd.0010018. eCollection 2021 Dec. PMID: 34914694
  3. Evaluation of a self-help intervention to promote the health and wellbeing of marginalised people including those living with leprosy in Nepal: a prospective, observational, cluster-based, cohort study with controls. Shrestha D, Napit IB, Ansari S, Choudhury SM, Dhungana B, Gill P, Griffiths F, Gwyther H, Hagge D, Kandel S, Puri S, Sartori J, Watson SI, Lilford R.BMC Public Health. 2021 May 6;21(1):873. doi: 10.1186/s12889-021-10847-0.PMID: 33957899
  4. An assessment of the reported impact of the COVID-19 pandemic on leprosy services using an online survey of practitioners in leprosy referral centres. de Barros B, Lambert SM, Negera E, de Arquer GR, Sales AM, Darlong J, Dias VLA, Rozario BJ, Pai VV, Alinda MD, Listiawan MY, Hagge DA, Shah M, Lockwood DNJ, Walker SL. Trans R Soc Trop Med Hyg. 2021 Jun 2:trab084. doi: 10.1093/trstmh/trab084. PMID: 34077950
  5. Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial. Barbara de Barros, Saba M Lambert, Mahesh Shah, Vivek V Pai, Joydeepa Darlong, Benjamin Jewel Rozario, Medhi Denisa Alinda, Anna M Sales, Shimelis Doni, Deanna A Hagge, Dilip Shrestha, M Yulianto Listiawan, Abeba M Yitaye, Jose A C Nery, Kapil D Neupane, Vivianne L A Dias, C Ruth Butlin, Peter G Nicholls, Diana Lockwood, Stephen L Walker. BMJ Open. 2020 Nov 17;10(11):e037700.
  6. Post-Exposure Prophylaxis (PEP) Efficacy of Rifampin, Rifapentine, Moxifloxacin, Minocycline, and Clarithromycin in a Susceptible-Subclinical Model of Leprosy. Lenz SM, Collins JH, Ray NA, Hagge DA, Lahiri R, Adams LB. PLoS Negl Trop Dis. 2020 Sep 16;14(9):e0008583. doi: 10.1371/journal.pntd.0008583. eCollection 2020 Sep.PMID: 32936818
  7. Whole Blood RNA Signatures in Leprosy Patients Identify Reversal Reactions Before Clinical Onset: a Prospective, Multicenter Study. Tió-Coma M, van Hooij A, Bobosha K, van der Ploeg-van Schip JJ, Banu S, Khadge S, Thapa P, Kunwar CB, Goulart IM, Bekele Y, Hagge DA, Moraes MO, Teles RMB, Pinheiro RO, van Zwet EW, Goeman JJ, Aseffa A, Haks MC, Ottenhoff THM, Modlin RL, Geluk A. Sci Rep. 2019 Nov 29;9(1):17931. doi: 10.1038/s41598-019-54213-y.
  8. Identification of a Systemic Interferon-γ Inducible Antimicrobial Gene Signature in Leprosy Patients Undergoing Reversal Reaction. Teles RMB, Lu J, Tió-Coma M, Goulart IMB, Banu S, Hagge D, Bobosha K, Ottenhoff THM, Pellegrini M, Geluk A, Modlin RL. PLoS Negl Trop Dis. 2019 Oct 10;13(10):e0007764. doi: 10.1371/journal.pntd.0007764. eCollection 2019 Oct.
  9. Diagnosis and Impact of Neuropathic Pain in Leprosy Patients in Nepal after Completion of Multidrug Therapy. Toh HS, Maharjan J, Thapa R, Neupane KD, Shah M, Baral S, Hagge DA, Napit IB, Lockwood DNJ. PLoS Negl Trop Dis. 2018 Jul 2;12(7): e0006610.
  10. Antimicrobial Resistance in Leprosy: Results of the First Prospective Open Survey Conducted by a WHO Surveillance Network for the Period 2009-15. Cambau E, Saunderson P, Matsuoka M, Cole ST, Kai M, Suffys P, Rosa PS, Williams D, Gupta UD, Lavania M, Cardona-Castro N, Miyamoto Y, Hagge D, Srikantam A, Hongseng W, Indropo A, Vissa V, Johnson RC, Cauchoix B, Pannikar VK, Cooreman EAWD, Pemmaraju VRR, Gillini L; WHO surveillance network of antimicrobial resistance in leprosy. Clin Microbiol Infect. 2018 Dec;24(12):1305-1310.
  11. Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial. Wagenaar I, Post E, Brandsma W, Bowers B, Alam K, Shetty V, Pai V, Husain S, Sigit Prakoeswa CR, Astari L, Hagge D, Shah M, Neupane K, Tamang KB; TENLEP study group, Nicholls P, Richardus JH. PLoS Negl Trop Dis. 2017 Oct 4;11(10):e0005952.
  12. Opening a Can of Worms: Leprosy Reactions and Complicit Soil-Transmitted Helminths. Hagge DA, Parajuli P, Kunwar CB, Rana DRSJB, Thapa R, Neupane KD, Nicholls P, Adams LB, Geluk A, Shah M, Napit IB. EBioMedicine. 2017 Sep;23:119-124.
  13. A Leprosy Clinical Severity Scale for Erythema Nodosum Leprosum: An International, Multicenter Validation Study of the ENLIST ENL Severity Scale. Walker SL, Sales AM, Butlin CR, Shah M, Maghanoy A, Lambert SM, Darlong J, Rozario BJ, Pai VV, Balagon M, Doni SN, Hagge DA, Nery JAC, Neupane KD, Baral S, Sangma BA, Alembo DT, Yetaye AM, Hassan BA, Shelemo MB, Nicholls PG, Lockwood DNJ; Erythema Nodosum Leprosum International STudy Group. PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005716
  14. Exploratory Urinary Metabolomics of Type 1 Leprosy Reactions. Mayboroda OA, van Hooij A, Derks R, van den Eeden SJ, Dijkman K, Khadge S, Thapa P, Kunwar CB, Hagge DA, Geluk A. Int J Infect Dis. 2016 Apr;45:46-52. doi: 10.1016/j.ijid.2016.02.012. Epub 2016 Feb 26.
  15. Genetic Variation in Toll-Interacting Protein Is Associated with Leprosy Susceptibility and Cutaneous Expression of Interleukin 1 Receptor Antagonist. Shah JA, Berrington WR, Vary JC Jr, Wells RD, Peterson GJ, Kunwar CB, Khadge S, Hagge DA, Hawn TR. J Infect Dis. 2016 Apr 1;213(7):1189-97. doi: 10.1093/infdis/jiv570. Epub 2015 Nov 26.
  16. Persistent Dengue Emergence: the 7 Years Surrounding the 2010 Epidemic in Nepal. Pandey BD, Pandey K, Neupane B, Shah Y, Adhikary KP, Gautam I, Hagge DA, Morita K. Trans R Soc Trop Med Hyg. 2015 Dec; 109(12):775-82. doi: 10.1093/trstmh/trv087. Epub 2015 Oct 26.
  17. Longitudinal Immune Profiles in Type 1 Leprosy Reactions in Bangladesh, Brazil, Ethiopia and Nepal. Khadge S, Banu S, Bobosha K, van der Ploeg-van Schip JJ, Goulart IM, Thapa P, Kunwar CB, van Meijgaarden KE, van den Eeden SJ, Wilson L, Kabir S, Dey H, Goulart LR, Lobato J, Carvalho W, Bekele Y, Franken KL, Aseffa A, Spencer JS, Oskam L, Otttenhoff TH, Hagge DA, Geluk A. BMC Infect Dis. 2015 Oct 28;15:477. doi: 10.1186/s12879-015-1128-0.
  18. ENLIST 1: an international multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum. Walker SL, Balagon M, Darlong J, Doni SN, Hagge DA, Halwai V, John A, Lambert SM, Maghanoy A, Nery JA, Neupane KD, Nicholls PG, Pai VV, Parajuli P, Sales AM, Sarno E, Shah M, Tsegaye D, Lockwood DN; Erythema Nodosum Leprosum International STudy Group. PLoS Negl Trop Dis. 2015 Sep 9;9(9):e0004065. doi: 10.1371/journal.pntd.0004065. eCollection 2015. PMID: 26351858
  19. Differential Dermal Expression of CCL17 and CCL18 in Tuberculoid and Lepromatous Leprosy. Berrington WR, Kunwar CB, Neupane KD, van den Eeden SJF, Vary JC, Peterson GJ, Wells RD, Geluk A, Hagge DA, and Hawn TR. PLoS Negl Trop Dis (accepted for publication)
  20. IL-10 and NOS2 Modulate Antigen-Specific Reactivity and Nerve Infiltration by T Cells in Experimental Leprosy. Hagge DA, Scollard DM, Ray NA, Marks VT, Deming AT, et al. (2014). PLoS Negl Trop Dis. 2014; 8(9): e3149. doi:10.1371/journal.pntd.0003149
  21. Safety and efficacy assessment of two new leprosy skin test antigens: randomized double blind clinical study. Rivoire BL, Groathouse NA, TerLouw S, Neupane KD, Ranjit C, Sapkota BR, Khadge S, Kunwar CB, Macdonald M, Hawksworth R, Thapa MB, Hagge DA, Tibbals M, Smith C, Dube T, She D, Wolff M, Zhou E, Makhene M, Mason R, Sizemore C, Brennan PJ.PLoS Negl Trop Dis. 2014 May 29;8(5):e2811. doi: 10.1371/journal.pntd.0002811. eCollection 2014.PMID: 24874401
  22. T-Cell Regulation in Lepromatous Leprosy. Bobosha K, Wilson L, van Meijgaarden KE, Bekele Y, Zewdie M, et al. (2014). PLoS Negl Trop Dis 8(4): e2773. doi:10.1371/journal.pntd.0002773
  23. Diagnosis and Treatment of Leprosy Reactions in Integrated Services--the Patients' Perspective in Nepal. Raffe SF, Thapa M, Khadge S, Tamang K, Hagge D, Lockwood DN. PLoS Negl Trop Dis. 2013;7(3):e2089. doi: 10.1371/journal.pntd.0002089. Epub 2013 Mar 7.
  24. Insights From Animal Models on the Immunogenetics of Leprosy: a Review. Adams LB, Pena MT, Sharma R, Hagge DA, Schurr E, Truman RW. Mem Inst Oswaldo Cruz. 2012 Dec; 107 Suppl 1:197-208.
  25. Comparison of Two Rapid Tests for Anti-Phenolic Glycolipid-I Serology in Brazil and Nepal. Stefani MM, Grassi AB, Sampaio LH, de Sousa AL, Costa MB, Scheelbeek P, Neupane KD, Hagge DA, Macdonald M, Cho SN, Oskam L, Bührer-Sékula S. Mem Inst Oswaldo Cruz. 2012 Dec; 107 Suppl 1:124-31.
  26. Mycobacterium leprae Virulence-Associated Peptides are Indicators of Exposure to M. leprae in Brazil, Ethiopia and Nepal. Bobosha K, Tang ST, van der Ploeg-van Schip JJ, Bekele Y, Martins MV, Lund O, Franken KL, Khadge S, Pontes MA, Gonçalves Hde S, Hussien J, Thapa P, Kunwar CB, Hagge DA, Aseffa A, Pessolani MC, Pereira GM, Ottenhoff TH, Geluk A. Mem Inst Oswaldo Cruz. 2012 Dec; 107 Suppl 1:112-23.
  27. Human Beta-Defensin 3 is Up-Regulated in Cutaneous Leprosy Type 1 Reactions. Cogen AL, Walker SL, Roberts CH, Hagge DA, Neupane KD, Khadge S, Lockwood DN. PLoS Negl Trop Dis. 2012;6(11):e1869. doi: 10.1371/journal.pntd.0001869. Epub 2012 Nov 1.
  28. A Comparison of the Change in Clinical Severity Scale Score and a Retrospective Physician Assessment of Neurological Outcome in Individuals with Leprosy Associated Nerve Function Impairment after Treatment with Corticosteroids. Walker SL, Nicholls PG, Dhakal S, Hawksworth RA, Macdonald M, Mahat K, Ruchal S, Hamal S, Hagge DA, Neupane KD, Lockwood DN. Lepr Rev. 2012 Jun;83(2):154-63.
  29. Immunogenicity of Mycobacterium leprae Unique Antigens in Leprosy Endemic Populations in Asia and Africa. Bobosha K, Van Der Ploeg-Van Schip JJ, Zewdie M, Sapkota BR, Hagge DA, Franken KL, Inbiale W, Aseffa A, Ottenhoff TH, Geluk A. Lepr Rev. 2011 Dec;82(4):445-58.
  30. The Effect of Systemic Corticosteroid Therapy on the Expression of Toll-Like Receptor 2 and Toll-Like Receptor 4 in the Cutaneous Lesions of Leprosy Type 1 Reactions. Walker SL, Roberts CH, Atkinson SE, Khadge S, Macdonald M, Neupane KD, Ranjit C, Sapkota BR, Dhakal S, Hawksworth RA, Mahat K, Ruchal S, Hamal S, Hagge DA, Lockwood DN. Br J Dermatol. 2012 July 167(1):29-35. doi: 10.1111/j.1365-2133.2012.10891.x. Epub 2012 Jun 1.
  31. Real-time PCR and High-Resolution Melt Analysis for Rapid Detection of Mycobacterium leprae Drug Resistance Mutations and Strain Types. Li W, Matsuoka M, Kai M, Thapa P, Khadge S, Hagge DA, Brennan PJ, Vissa V. J Clin Microbiol. 2012 Mar; 50(3):742-53. doi: 10.1128/JCM.05183-11. Epub 2011 Dec 14.
  32. A Phase Two Randomised Controlled Double Blind Trial of High Dose Intravenous Methylprednisolone and Oral Prednisolone Versus Intravenous Normal Saline and Oral Prednisolone in Individuals with Leprosy Type 1 Reactions and/or Nerve Function Impairment. Walker SL, Nicholls PG, Dhakal S, Hawksworth RA, Macdonald M, Mahat K, Ruchal S, Hamal S, Hagge DA, Neupane KD, Lockwood DN. PLoS Negl Trop Dis. 2011 Apr 12;5(4):e1041. doi: 10.1371/journal.pntd.0001041.
  33. Common Polymorphisms in the NOD2 Gene Region are Associated with Leprosy and Its Reactive States. Berrington WR, Macdonald M, Khadge S, Sapkota BR, Janer M, Hagge DA, Kaplan G, Hawn TR. J Infect Dis. 2010 May 1; 201(9):1422-35. doi: 10.1086/651559.
  34. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Tobin DM, Vary JC Jr, Ray JP, Walsh GS, Dunstan SJ, Bang ND, Hagge DA, Khadge S, King MC, Hawn TR, Moens CB, Ramakrishnan L.Cell. 2010 Mar 5; 140(5):717-30. doi: 10.1016/j.cell.2010.02.013.PMID: 20211140
  35. Lymphotoxin-Alpha and TNF Have Essential but Independent Roles in the Evolution of the Granulomatous Response in Experimental Leprosy. Hagge DA, Saunders BM, Ebenezer GJ, Ray NA, Marks VT, Britton WJ, Krahenbuhl JL, Adams LB. Am J Pathol. 2009 Apr; 174(4):1379-89. doi: 10.2353/ajpath.2009.080550. Epub 2009 Feb 26.
  36. Emergence of an Effective Adaptive Cell mediated Immune Response to Mycobacterium leprae is Not Impaired in Reactive Oxygen Intermediate-Deficient Mice. Hagge DA, Marks VT, Ray NA, Dietrich MA, Kearney MT, Scollard DM, Krahenbuhl JL, Adams LB. FEMS Immunol Med Microbiol. 2007 Oct; 51(1):92-101. Epub 2007 Jul 20.
  37. An in vitro Model for the Lepromatous Leprosy Granuloma: Fate of Mycobacterium leprae From Target Macrophages after Interaction with Normal and Activated Effector Macrophages. Hagge DA, Ray NA, Krahenbuhl JL, Adams LB. J Immunol. 2004 Jun 15; 172(12):7771-9.
  38. A New Model for Studying the Effects of Mycobacterium leprae on Schwann Cell and Neuron Interactions. Hagge DA, Oby Robinson S, Scollard D, McCormick G, Williams DL. J Infect Dis. 2002 Nov 1; 186(9):1283-96. Epub 2002 Oct 8.